EUVIMEDEUVIMED entdecken
Multizentrische Studie

High Responsiveness of Head and Neck Kaposiform Hemangioendothelioma Without Kasabach–Merritt Phenomenon to Sirolimus Monotherapy

Yulang Xu iD, Jiangyuan Zhou, Yuru Lan, Linyu Yang, Yunhan Zhang, Yi Ji iD

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70635 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Yulang Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Pediatric Surgery, and Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, People's Republic …. Hauptthemen laut MEDLINE: Sirolimus, Hemangioendothelioma, Sarcoma, Kaposi, Head and Neck Neoplasms. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Excellent Youth Foundation of Sichuan Province of China, Med-X Center for Informatics Funding Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Sirolimus is the cornerstone therapy for Kaposiform hemangioendothelioma (KHE). The purpose of this study was to evaluate whether anatomical location independently predicts radiologic response to sirolimus monotherapy in KHE without Kasabach–Merritt phenomenon (KMP). Patients and Methods We included 21 patients with head and neck KHE without KMP and 50 matched patients with non‐head and neck KHE without KMP, all treated with sirolimus monotherapy in five tertiary referral centers in China. The primary outcome was the 12‐month radiologic response rate (defined as ≥ 20% tumor volume reduction on MRI). The Cochran–Mantel–Haenszel test was used to adjust for matching factors, and multivariate logistic regression was performed to identify independent predictors of treatment response.

Results

The head and neck group achieved a 100% 12‐month radiologic response rate versus 76% in the non‐head and neck group (adjusted p = 0.012). A near‐complete involution rate was 81% versus 44% (adjusted p = 0.003). Multivariate analysis confirmed that head and neck location was the only independent predictor of both radiologic response (OR = 12.34, 95% CI: 1.45–105.21, p = 0.021) and near‐complete involution (OR = 5.87, 95% CI: 1.89–18.23, p = 0.002). No disease progression occurred in head and neck cases, while 4% of non‐head and neck lesions progressed. Safety and quality‐of‐life outcomes were comparable between groups.

Conclusion

Anatomical location is a significant independent predictor of sirolimus monotherapy efficacy in KHE without KMP. The exceptional radiologic response rate and favorable safety profile support sirolimus monotherapy as a sufficient first‐line therapy for head and neck KHE, providing evidence for location‐based precision treatment strategies. Trial Registration ClinicalTrials.gov identifier: NCT04775173. Summary What is known about this subject: Kaposiform hemangioendothelioma (KHE) without Kasabach–Merritt phenomenon (KMP) can cause functional impairments, but sirolimus is used as therapy. Efficacy of sirolimus monotherapy may vary by anatomical location, though evidence is limited. This study aimed to evaluate location‐specific responses to address this gap. What this study adds: Head and neck KHE lesions exhibit a prominent response to sirolimus monotherapy, with 100% radiologic response at 12 months, which is an independent predictor of treatment efficacy. Near‐complete involution was higher in head and neck cases (81% vs. 44%), with no disease progression. Sirolimus monotherapy is recommended for head and neck KHE without KMP, while non‐head and neck lesions may need aggressive approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusHemangioendotheliomaSarcoma, KaposiHead and Neck NeoplasmsKasabach-Merritt SyndromeAntibiotics, AntineoplasticHumansFemaleMaleChild, PreschoolChildFollow-Up StudiesInfantAdolescentPrognosis

Stichwörter der Autor:innen

Kaposiform hemangioendotheliomaKasabach–Merritt phenomenonanatomical locationmulticenter cohort studysirolimustargeted therapy

Substanzen

SirolimusAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Division of Oncology, Department of Pediatric Surgery, and Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

ORCID-Profile: Yulang Xu, Yi Ji

Förderung

  • National Natural Science Foundation of China
  • Excellent Youth Foundation of Sichuan Province of China
  • Med-X Center for Informatics Funding Project
  • Project for Disciplines of Excellence Clinical Research Incubation Project of West China Hospital of Sichuan University
  • Project for Disciplines of Excellence Clinical Research Interdisciplinary Innovation Project of West China Hospital of Sichuan University
  • Project of '0-1' of Sichuan University

Zitieren

APA

Xu, Y., Zhou, J., Lan, Y., Yang, L., Zhang, Y., & Ji, Y. (2026). High Responsiveness of Head and Neck Kaposiform Hemangioendothelioma Without Kasabach–Merritt Phenomenon to Sirolimus Monotherapy. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70635

Vancouver

Xu Y, Zhou J, Lan Y, Yang L, Zhang Y, Ji Y. High Responsiveness of Head and Neck Kaposiform Hemangioendothelioma Without Kasabach–Merritt Phenomenon to Sirolimus Monotherapy. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70635

BibTeX
@article{Xu2026,
  author = {Xu, Yulang and Zhou, Jiangyuan and Lan, Yuru and Yang, Linyu and Zhang, Yunhan and Ji, Yi},
  title = {High Responsiveness of Head and Neck Kaposiform Hemangioendothelioma Without Kasabach–Merritt Phenomenon to Sirolimus Monotherapy},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70635}
}
Kostenlos starten →